10-Q: CIMG Inc. Reports Q2 2026 Results Amid Nasdaq Delisting

CIMG Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing significant revenue growth driven by new product series, but also highlighting substantial net losses and ongoing concerns about its ability to continue as a going concern.

Summary

• CIMG Inc. reported revenues of $3,214,991 for the three months ended March 31, 2026, a significant increase from $0 in the prior year period, driven by sales from its Maca, Homology of Medicine and Food, and Computing Power Product series.
• The company incurred a net loss of $15,434,637 for the three months ended March 31, 2026, compared to a net loss of $385,556 in the same period of 2025, largely due to increased operating expenses and fair value adjustments on digital assets.
• As of March 31, 2026, the company held 730 Bitcoins with a carrying amount of $49,847,670.
• The company's common stock was delisted from The Nasdaq Stock Market on March 6, 2026, and is now quoted on the OTC market under the symbol CIMG.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses, negative cash flows, and a limited cash balance of $17,025 as of March 31, 2026.
• Management plans to address these concerns by seeking additional equity or debt financing and executing a revised business strategy, but these plans have not alleviated the doubt.
• Operating expenses increased by 77.74% to $1,337,791 for the three months ended March 31, 2026, primarily due to higher labor costs and professional fees.
• The company's gross profit margin significantly decreased from 67.73% in the six months ended March 31, 2025, to 0.53% in the six months ended March 31, 2026, attributed to discounted sales and a shift in revenue mix.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the significant increase in net losses, sharp decline in gross margins, drastically reduced cash reserves, and the delisting from Nasdaq, all pointing to severe financial distress and going concern issues.

Positives

• Significant revenue growth, with total revenue reaching $3,214,991 for the three months ended March 31, 2026, compared to $0 in the prior year period.
• Successful launch and contribution to revenue from new product series: Homology of Medicine and Food, Computing Power Product, and Maca Product Series.
• The Maca Product Series generated $12,118,011 in revenue for the six months ended March 31, 2026, representing 63.83% of total revenue.
• The Computing Power Product Series generated $5,010,158 in revenue for the six months ended March 31, 2026, representing 26.39% of total revenue.
• The company has secured exclusive distribution and sales rights in Asia for Kangduoyuan brand Maca products for a three-year term.
• The company is expanding its sales and distribution channels in Asia to encompass a broader range of consumer food and beverage products.

Negatives

• Incurred a net loss of $15,434,637 for the three months ended March 31, 2026, a substantial increase from $385,556 in the prior year period.
• The company has an accumulated deficit of approximately $122.10 million as of March 31, 2026.
• Cash balance significantly decreased to $17,025 as of March 31, 2026, raising substantial doubt about the company's ability to continue as a going concern.
• Gross profit margin declined sharply from 67.73% in the six months ended March 31, 2025, to 0.53% in the six months ended March 31, 2026.
• Operating expenses increased by 77.74% to $1,337,791 for the three months ended March 31, 2026.
• The company's common stock was delisted from The Nasdaq Stock Market on March 6, 2026.
• Disclosure controls and procedures, and internal control over financial reporting were found to be not effective as of March 31, 2026.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and insufficient cash reserves.
• The company's reliance on future financing, which is not assured, to fund operations beyond the next twelve months.
• The significant market volatility of digital assets (Bitcoin) held by the company, which may not represent assured sources of financing.
• The potential for further delisting from trading platforms if the company cannot regain compliance with listing rules.
• The company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and its Quarterly Report on Form 10-Q for the period ended December 31, 2025, led to Nasdaq delisting.
• Ongoing legal proceedings, including the Kim Litigation and the Ex-Directors Lawsuit, which could result in significant monetary damages.
• The company's business strategy relies on expanding sales and distribution channels in Asia, which may be subject to regulatory and economic uncertainties.
• The company's dependence on key suppliers and customers, as highlighted by the concentration of revenue from Customer ZNF (63.83%) and purchases from suppliers YKZS, ACJN, and TTY.

Future Outlook

The company expects to need additional capital to fund its planned operations beyond the next twelve months. Management is pursuing additional equity or debt financing and executing a revised business strategy to address its going concern issues. The company has not yet achieved profitability and anticipates continued significant sales and marketing expenses.

Management Comments

• Management acknowledges that the company has incurred recurring losses and negative cash flows from operations since inception and that there is substantial doubt about its ability to continue as a going concern.
• Management plans to address these conditions by raising additional equity or debt financing and executing its revised business strategy.
• Management believes that the terms of related party transactions are not materially different from those that could have been obtained from independent third parties under similar circumstances.
• Management has concluded that substantial doubt about the Company's ability to continue as a going concern has not been alleviated.

Industry Context

StockSavvy.ai notes that CIMG Inc.'s strategic shift from specialty coffee to health and wellness products, including Maca-based items and exosome eye drops, aligns with broader market trends favoring health-conscious consumer goods. The expansion into computing power products, leveraging AI, also reflects the growing demand for advanced technology solutions in the Asian market. However, the company's Nasdaq delisting and ongoing financial struggles present significant headwinds.

Comparison to Industry Standards

• The company's gross profit margin of 0.53% for the six months ended March 31, 2026, is significantly lower than typical margins for consumer goods companies, which often range from 20% to 50% depending on the product category.
• The substantial increase in operating expenses (77.74% for the quarter) outpaced revenue growth, indicating potential inefficiencies or significant investment in new ventures, which is a common challenge for companies undergoing transformation but requires careful management to avoid further financial strain.
• The company's net loss of $15.4 million for the quarter is substantial relative to its revenue, highlighting a critical need for improved cost management and revenue generation strategies to achieve profitability, a benchmark for sustainable business operations.

Corporate Governance

Legal Proceedings

• The Kim Litigation: Mr. Sooncha Kim filed a complaint alleging breach of a Convertible Note and Warrant Purchase Agreement, seeking specific performance and monetary damages of $1,041,216 plus interest.
• The Ex-Directors Lawsuit: Former directors filed a complaint alleging failure to pay directors fees and expenses, resulting in a default judgment of $222,062.28.

Related Party Transactions

• Significant transactions with related parties include loans advanced to and from entities and individuals associated with the company's management and shareholders.
• Balances with related parties include amounts due from and to entities such as Wenwen Yu, Yanli Hou, Dada Business Trading Co., Limited, and YY Tech Inc.
• Management believes the terms of these transactions are not materially different from those with independent third parties.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to future capital raises and ongoing financial distress. The delisting from Nasdaq also impacts liquidity and market perception.
• Creditors: The company's going concern issues and substantial deficit may impact its ability to meet its obligations.
• Employees: Uncertainty regarding the company's future operations could affect job security.
• Suppliers: The company's financial instability may lead to payment delays or disruptions in supply chains.
• Customers: While new product lines are being introduced, the company's financial health could impact product availability and support.

Next Steps

• Management plans to seek additional equity or debt financing.
• Management plans to execute its revised business strategy.
• The company is undergoing an appeal process for the Nasdaq delisting decision.
• The company will continue to operate on the OTC market under the symbol CIMG.
• The company will continue to develop and market its Homology of Medicine and Food Series, Computing Power Product Series, and Maca Product Series.
• The company is subject to ongoing legal proceedings that may impact its financial condition.

Key Dates

Recommendation

The company exhibits severe financial distress, characterized by substantial net losses, a sharp decline in gross margins, critically low cash reserves, and a going concern warning. The delisting from Nasdaq further exacerbates these issues, indicating a high level of risk for investors. While there is revenue growth, it is not translating into profitability, and the company's ability to secure future financing is uncertain. The ongoing legal proceedings add further downside risk.

Keywords

CIMG Inc., Form 10-Q, Quarterly Report, Financial Statements, Revenue Growth, Net Loss, Going Concern, Nasdaq Delisting, Digital Assets, Bitcoin, Maca Products, Computing Power, Operating Expenses, Gross Margin, Equity Financing